These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32141321)

  • 21. Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non-Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy.
    Cho A; Kranawetter B; Untersteiner H; Khalaveh F; Dorfer C; Rössler K; Zöchbauer-Müller S; Gatterbauer B; Hochmair MJ; Frischer JM
    World Neurosurg; 2021 Jul; 151():e324-e331. PubMed ID: 33878466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
    Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
    Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
    Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Significance of Dynamic Neutrophil-lymphocyte Ratio Changes in Patients With Colorectal Cancer.
    Ashizawa N; Furuya S; Katsutoshi S; Sudo M; Akaike H; Hosomura N; Kawaguchi Y; Amemiya H; Kawaida H; Inoue S; Kono H; Ichikawa D
    Anticancer Res; 2020 Apr; 40(4):2311-2317. PubMed ID: 32234931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer.
    Wang J; Kalhor N; Hu J; Wang B; Chu H; Zhang B; Guan Y; Wu Y
    PLoS One; 2016; 11(10):e0163397. PubMed ID: 27695079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined C-reactive protein and Neutrophil to Lymphocyte ratio use predict survival innon-small-cell lung cancer.
    Bacha S; Sghaier A; Habibech S; Cheikhrouhou S; Racil H; Chaouch N; Zaouri B; Chabbou A
    Tunis Med; 2017 Dec; 95(12):229-235. PubMed ID: 29878284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC.
    Guo M; Li W; Li B; Zou B; Wang S; Meng X; Sun X; Yu J; Wang L
    Int Immunopharmacol; 2019 Jul; 72():395-401. PubMed ID: 31030095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
    Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
    [No Abstract]   [Full Text] [Related]  

  • 31. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
    Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
    Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Yao Y; Yuan D; Liu H; Gu X; Song Y
    Cancer Immunol Immunother; 2013 Mar; 62(3):471-9. PubMed ID: 22986452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
    Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients.
    Guo D; Han A; Jing W; Chen D; Jin F; Li M; Kong L; Yu J
    Future Oncol; 2018 May; 14(12):1187-1196. PubMed ID: 29302993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
    Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
    Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postoperative Elevations of Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratios Predict Postoperative Pulmonary Complications in Non-small Cell Lung Cancer Patients: A Retrospective Cohort Study.
    Wang Y; Hu X; Su MC; Wang YW; Che GW
    Curr Med Sci; 2020 Apr; 40(2):339-347. PubMed ID: 32337695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.